Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence

Journal of Diabetes and its Complications

Volumn 30, Issue 6, 2016, Pages 981-985

  Davidson, Mayer B ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Actos; Bladder cancer; CVD; Legal system; Pioglitazine

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

BLADDER CANCER; CANCER RISK; DISEASE ASSOCIATION; DRUG INDUSTRY; EMOTIONAL STRESS; EVIDENCE BASED MEDICINE; HUMAN; LAW SUIT; PRIORITY JOURNAL; REVIEW; BLADDER TUMOR; CHEMICALLY INDUCED; FEMALE; LEGISLATION AND JURISPRUDENCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR;

DIABETES MELLITUS, TYPE 2; DRUG INDUSTRY; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; RISK FACTORS; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84964615083     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2016.04.004     Document Type: Review

References (47)

1. Althouse, A.D., Abbott, J.D., Sutton-Tyrrell, K., Forker, A.D., Lombardero, M.S., Buttron, L.V.,.. Brooks, M.M., for the BARI 2D STUDY GROUP. Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care 37 (2014), 1346–1352.
2. Azoulay, L., Yin, H., Filin, K.B., Assayag, J., Majdan, A., Pollak, M.N.,.. Suissa, A.S., The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: Nested case–control study. BMJ, 244, 2012, e3645.
3. Brennan, P., Bogillot, O., Cordier, S., Greiser, E., Schill, W., Vineis, P.,.. Bofetta, P., Cigarette smoking and bladder cancer in men: A pooled analysis of 11 case–control studies. International Journal of Cancer 86 (2000), 289–294.
4. Burger, M., Catto, J.W.F., Dalbagni, G., Grossman, H.B., Herr, H., Karakiewicz, P.,.. Lotan, Y., Epidemiology and risk factors of urothelial bladder cancer. European Urology 63 (2013), 234–241.
5. Chang, C.-H., Lin, J.-W., Wu, L.-C., Lai, M.-S., Chuang, L.-M., Chan, E.A., Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 55 (2012), 1462–1472.
6. Dormandy, J.A., Betteridge, D.J., Schernthaner, G., Pirags, V., Norgren, L., on behalf of the PROactive investigators. Impact of peripheral arterial disease in patients with diabetes-results from PROactive (PROactive 11). Atherosclerosis 202 (2009), 272–281.
7. Dormandy, J.A., Charbonnel, B., Eckland, D.J.A., Erdmann, E., Massi-Benedetti, M., Maules, I.K.,.. Smith U on behalf of the PROactive investigators, Secondary prevention of macrovascular events in patients with type 1 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomized controlled trial. Lancet 366 (2005), 1279–1289.
8. Drugs.com U.S. Sales statistics for Actos prescriptions. (accessed November 11, 2015).
9. Erdmann, E., Dormandy, J.A., Charbonnel, B., Massi-Benedetti, M., Moules, I.K., Skene, A.M., on behalf of the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. Journal of the American College of Cardiology 49 (2007), 1772–1780.
10. Erdmann, E., Harding, S., Perez, A., Ten-year observational follow-up of PROactive: A randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes, Obesity & Metabolism 18 (2016), 266–273.
11. Fujimoto, K., Hamamoto, Y., Honjo, S., Kawasaki, Y., Mori, K., Tatsuoka, H.,.. Koshiyama, H., Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. Diabetes Research and Clinical Practice 99 (2013), e21–e23.
12. Heneka, M.T., Fink, A., Doblhammer, G., Effect of pioglitazone medication on the incidence of dementia. Annals of Neurology 78 (2015), 284–294.
13. Hsiao, F.-Y., Hsieh, P.-H., Huang, W.-F., Tsai, Y.-W., Gau, C.-S., Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: A nested case–control study. Drug Safety 36 (2013), 643–649.
14. http://www.fda.gov/Drugs/DrugSafety/ucm226214.htm (accessed November 15, 2015).
15. Jin, S.-M., Song, S.O., Jung, C.H., Chang, J.-S., Suh, S., Kang, S.M.,.. Lee, B-W., Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: A multi-center retrospective cohort study. Journal of Korean Medical Science 29 (2014), 238–242.
16. Korhonen, P., Heintjes, E.M., Williams, R., Hoti, F., Christopher, S., Majak, M.,.. Bahmanyar, S., Bladder cancer risk in relation to exposure to pioglitazone among patients with T2DM in the Pan European Multi-Database Bladder Cancer Risk Characterization Study. American Diabetes Association 75th Scientific Sessions, Boston MA, June, 2015, late breaking abstract, 2015.
17. Kuo, H.-W., Tiao, M.-M., Ho, S.-C., Yang, C.-Y., Pioglitazone use and the risk of bladder cancer. Kaohsiung Journal of Medical Sciences 30 (2014), 94–97.
18. Lee, M.-Y., Hsiao, P.-J., Yang, Y.-H., Lin, K.-D., Shin, S.-J., The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese; bladder cancer and chronic kidney. PLoS One, 9, 2014, e85479.
19. Levin, D., Bell, S., Sund, R., Hartikainen, S.A., Tuomilehto, J., Pukkala, E.,.. Colhoun H.M. on behalf of the Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium, Pioglitazone and bladder cancer risk: A multipopulation pooled, cumulative exposure analysis. Diabetologia 58 (2015), 493–504.
20. Lewis, J.D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W.B., Quesenberry, C.P.,.. Strom, B.L., Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 34 (2011), 916–922.
21. Lewis, J.D., Habel, L.A., Quesenberry, C.P., Strom, B.L., Peng, T., Hedderson, M.M., Ferrara, A., Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314 (2015), 265–277.
22. Lin, H.C., Hsu, Y.T., Kachingwe, B.H., Hsu, C.Y., Uang, Y.S., Wang, L.H., Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: A six-year population-based study. Journal of Clinical Pharmacy and Therapeutics 39 (2014), 354–360.
23. Lincoff, A.M., Wolski, K., Nicholls, S.J., Nissen, S.E., Pioglitazone and risk of cardiovascular events in patient with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA 298 (2007), 1180–1188.
24. Mamtani, R., Haynes, K., Bilker, W.E., Vaughan, D.J., Strom, B.L., Glanz, K.,.. Lewis, J.D., Association between longer therapy with thiazolidinediones and risk of bladder cancer: A cohort study. Journal of the National Cancer Institute 104 (2012), 1411–1421.
25. Mannucci, E., Monami, M., Lamanna, C., Gensini, G.F.,.. Marchionni, N., Pioglitzone and cardiovascular risk: A comprehensive meta-analysis of randomized clinical trials. Diabetes, Obesity & Metabolism 10 (2008), 1221–1238.
26. Mazzone, T., Meyer, P.M., Feinstein, S.B., Davidson, M.H., Kondos, G.T., D'Agostino, R.B.,.. Haffner, S.M., Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: A randomized trial. JAMA 296 (2006), 2572–2581.
27. Neumann, A., Weill, A., Ricordeau, P., Fagot, J.P., Alla, F., Allemand, H., Pioglitazone and risk of bladder cancer among diabetic patients in France: A population-based study. Diabetologia 55 (2012), 1953–1962.
28. Nissen, S.E., Nicholls, S.J., Wolski, K., Nesto, R., Kupfer, S., Perez, A.,.. Tuzcu E.M.: PERISCOPE, Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA 299 (2008), 1561–1573.
29. http://www.nytimes.com/2015/04/29/business/takeda-agrees-to-pay-2-4-billion-to-settle-suits-over-cancer-risk-of-actos.html (accessed November 15, 2015).
30. Oliveria, S.A., Koro, C.E., Yood, M.U., Sowell, M., Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metabolic Syndrome: Clinical Research & Reviews 2 (2008), 47–57.
31. Patel, D., Walitt, B., Lindsay, J., Wilensky, R.L., Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: A meta-analysis. JACC. Cardiovascular Interventions 4 (2011), 353–360.
32. Perez, A.T., Pioglitazone and risk of bladder cancer: Clarification of the design of the French study. Diabetologia, 56, 2013, 227.
33. Ryder, R.E.J., Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. Diabetic Medicine 32 (2014), 305–313.
34. SEER Cancer Statistics Factsheets: Bladder Cancer, National Cancer Institute. Bethesda, MD, ( http://seer.cancer.gov/stafacts/html/urinb.html).
35. Song, S.O., Kim, K.J., Lee, B.-W.L., Kang, E.S., Cha, B.S., Lee, H.C., The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone. Diabetes and Metabolism Journal 36 (2012), 371–378.
36. Sun, G.E.C., Wells, B.J., Yip, K., Zimmerman, R., Raghaven, D., Kattan, M.W.,.. Kashyap, S.R., Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 16 (2013), 276–283.
37. Tran, M.T., Navar, M.D., Davidson, M.B., Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes mellitus. Diabetes Care 29 (2006), 1395–1396.
38. Tseng, C.-H., Diabetes and risk of bladder cancer: A study using the National Health Insurance database in Taiwan. Diabetologia 54 (2011), 2009–2015.
39. Tseng, C.-H., Pioglitazone and bladder cancer: A population-based study of Taiwanese. Diabetes Care 35 (2012), 278–280.
40. Tzoulaki, J., Molokhia, M., Curcin, V., Little, M.P., Millett, C.J., Ng, A.,.. Elliott, P., Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database. BMJ, 339, 2009, b4731.
41. U.K. Prospective Diabetes Study Group, Overview of 6 years of type II diabetes: A progressive disease. Diabetes 44 (1995), 1249–1258.
42. Vallarino, C., Perez, A., Fusco, G., Liang, H., Bron, M., Manne, S.,.. Yu, S., Comparing piolgitazone to insulin with respect to cancer, cardiovascular and bone fractures endpoints, using propensity score weights. Clinical Drug Investigation 33 (2013), 621–631.
43. Wei, L., Pioglitazone and bladder cancer: A propensity score matched cohort study. British Journal of Clinical Pharmacology 75 (2012), 254–259.
44. Welty, C.J., Wright, J.L., Hotaling, J.M., Bhatti, P., Porter, M.P., White, E., Persistence of urothelial carcinoma of the bladder risk among former smokers: Results from a contemporary, prospective cohort study. Urologic Oncology: Seminars and Original Investigations, 2012, 1–5.
45. Wilcox, R., Bousser, M.-G., Betteridge, J., Schernthaner, G., Kupfer, S., Dormandy, J., for the PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial macroVascular Events 04). Stroke 38 (2007), 865–873.
46. Yang, J., Vallarino, C., Bron, M., Perez, A., Liang, H., Joseph, G.,.. Yu, S., A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: An expanded analysis from a retrospective cohort study. Current Medical Research and Opinion 30 (2014), 2223–2231.
47. Yokoyama, H., Araki, S., Kawai, K., Oishi, M., A, H., Sugimoto, K., Sone, H.,.. Kashiwagi, A., on behalf of Japan Diabetes Clinical Data Management Study Group. Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36). Diabetes Research and Clinical Practice 109 (2015), 485–492.